Everything below concerns PPARδ. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Born Mary Morse Baker on a farm in Bow, New Hampshire, Eddy was the youngest of six children in a family of Protestant Congregationalists. Her father, Mark Baker, was a deeply religious man, although, according to one account, "Christianity to him was warfare against sin, not a religion of human brotherhood." In common with most women at the time Eddy was given little formal education, but she said she had read widely at home. From childhood she lived with protracted ill health, complaining of chronic indigestion and spinal inflammation, and according to biographers experiencing fainting spells. The literary critic Harold Bloom described her as "a kind of anthology of nineteenth-century nervous ailments". Eddy's first husband died just before her 23rd birthday, six months after they married and three months before their son was born, leaving her penniless; as a result of her poor health she lost custody of the boy when he was four. Her second husband left her after 13 years of marriage; Eddy said that he had promised to become her child's legal guardian, but it is unclear whether he did, and Eddy lost contact with her son until he was in his thirties. (Per the legal doctrine of coverture, women in the United States could not then be their own children's guardians.) Her third husband, Asa Gilbert Eddy, died five years after they married; she believed he had been killed by malicious animal magnetism. Six years later, when she was 67 and apparently in need of loyalty and affection, she legally adopted a 41-year-old homeopath as her second son.
Fluorescent reporter probes detect only the DNA containing the sequence complementary to the probe; therefore, use of the reporter probe significantly increases specificity, and enables performing the technique even in the presence of other dsDNA. Using different-coloured labels, fluorescent probes can be used in multiplex assays for monitoring several target sequences in the same tube. The specificity of fluorescent reporter probes also prevents interference of measurements caused by primer dimers, which are undesirable potential by-products in PCR. However, fluorescent reporter probes do not prevent the inhibitory effect of the primer dimers, which may depress accumulation of the desired products in the reaction. The method relies on a DNA-based probe with a fluorescent reporter at one end and a quencher of fluorescence at the opposite end of the probe. The close proximity of the reporter to the quencher prevents detection of its fluorescence; breakdown of the probe by the 5' to 3' exonuclease activity of the Taq polymerase breaks the reporter-quencher proximity and thus allows unquenched emission of fluorescence, which can be detected after excitation with a laser. An increase in the product targeted by the reporter probe at each PCR cycle therefore causes a proportional increase in fluorescence due to the breakdown of the probe and release of the reporter.
Colin Ayton Greenhalgh, Principal, Hills Road Sixth Form College, Cambridge. For services to Education. Ian Gregg, Chairman, River Tweed Commissioners and Tweed Foundation. For services to Salmon and Trout Fishing. Vernon Charles Grove, Administrator, Wales and Chester Circuit, Lord Chancellor's Department. Rex Farrow Gyngell, . For political and public service. Arthur Barry Haines, Chair, Aerodynamics Group, Royal Aeronautical Society. For services to Aerodynamics. Eunice Hanna. For political service. Lieutenant Colonel Grattan Herbert Hart, . For services to the Royal British Legion in Sussex. Robert James Hasson, Assistant Controller (Collection and Personnel), Board of Inland Revenue. Anthony Roger Heath. For services to the Administration of Justice. Jennifer Mary Toresen, Lady Hemingford. For services to the community in Hemingford Abbots, Cambridgeshire and to the British Red Cross Society. Desmond Charles Henley, Embalmer. For services in the Aftermath of Disasters. Damon Graham Hill. For services to Motor Racing. John William Hoaen, Grade 7, Department of Trade and Industry. Margaret Edith Hobrough, Principal and Chief Executive, Godalming Sixth Form College, Surrey. For services to Education. Brigadier David Hendry Hodge, . For services to the Territorial Auxiliary and Volunteer Reserve Association in the North of England. The Reverend Roger Graham Holloway. For services to Export. John Hood. For services to Industry. John Trevor Hopkins, Headmaster, Bishop Stopford School, Kettering, Northamptonshire. For services to Education.
Sources: en.wikipedia.org
Collagen hybridizing peptide (CHP) staining allows for an easy, direct way to stain denatured collagens of any type (Type I, II, IV, etc.) regardless if they were damaged or degraded via enzymatic, mechanical, chemical, or thermal means. They work by refolding into the collagen triple helix with the available single strands in the tissue. CHPs can be visualized by a simple fluorescence microscope.
=== Japanese Army denialism === Although the identification of beriberi as a deficiency syndrome was proven beyond a doubt by 1913, a Japanese group headed by Mori Ōgai and backed by Tokyo Imperial University continued to deny this conclusion until 1926. In 1886, Mori, then working in the Japanese Army Medical Bureau, asserted that white rice was sufficient as a diet for soldiers. Simultaneously, Navy surgeon general Takaki Kanehiro published the groundbreaking results described above. Mori, who had been educated under German doctors, responded that Takaki was a "fake doctor" due to his lack of prestigious medical background, while Mori himself and his fellow graduates of Tokyo Imperial University constituted the only "real doctors" in Japan and that they alone were capable of "experimental induction", although Mori himself had not conducted any beriberi experiments. The Japanese Navy sided with Takaki and adopted his suggestions. To prevent the Army and himself from losing face, Mori assembled a team of doctors and professors from Tokyo Imperial University and the Japanese Army, who proposed that beriberi was caused by an unknown pathogen, which they described as etowasu (from the German etwas, meaning "something"). They employed various social tactics to denounce vitamin deficiency experiments and prevent them from being published, while beriberi ravaged the Japanese Army. During the First Sino-Japanese War and Russo-Japanese War, Army soldiers continued to die in mass numbers from beriberi, while Navy sailors survived.
=== Biosynthesis === Among the diverse pathways by which natural taurine can be biosynthesized, its pathways in the human liver are from cysteine and/or methionine. With regard to the route from cysteine: mammalian taurine synthesis occurs in the liver via the cysteine sulfinic acid pathway. In this pathway, cysteine is first oxidized to its sulfinic acid, catalyzed by the enzyme cysteine dioxygenase. Cysteine sulfinic acid, in turn, is decarboxylated by sulfinoalanine decarboxylase to form hypotaurine. Hypotaurine is enzymatically oxidized to yield taurine by hypotaurine dehydrogenase. Taurine is also produced by the transsulfuration pathway, which converts homocysteine into cystathionine. The cystathionine is then converted to hypotaurine by the sequential action of three enzymes: cystathionine gamma-lyase, cysteine dioxygenase, and cysteine sulfinic acid decarboxylase. Hypotaurine is then oxidized to taurine as described above. A pathway for taurine biosynthesis from serine and sulfate is reported in microalgae, developing chicken embryos, and chick liver. Serine dehydratase converts serine to 2-aminoacrylate, which is converted to cysteic acid by 3′-phosphoadenylyl sulfate:2-aminoacrylate C-sulfotransferase. Cysteic acid is converted to taurine by cysteine sulfinic acid decarboxylase.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.